ArticleObstetrics & gynecology science2026
Intravaginal magnesium sulfate as an alternative to intravenous dexamethasone for labor acceleration: first direct comparison in a bayesian adaptive trial.
Article in Obstetrics & gynecology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveLabor acceleration remains a major challenge in obstetric care. Although intravenous (IV) dexamethasone has been shown to be effective for labor acceleration, its systemic adverse effects limit its use. Intravaginal magnesium sulfate (MgSO4) may offer a potential alternative; however, comparative studies are needed. This study compared the safety and efficacy of these interventions for labor acceleration.
methodsThis Bayesian adaptive, three-arm randomized controlled trial enrolled 150 women in latent labor and assigned them to receive intravaginal MgSO4 (50%; 10 mL), IV dexamethasone (8 mg), or usual care. The primary outcomes were labor duration and change in Bishop score; secondary outcomes included Apgar scores.
resultsBoth active treatments significantly improved Bishop scores compared with control at 6 hours (3.06 vs. 3.05 points; P<0.001), with no significant difference between them. However, intravaginal MgSO4 reduced labor duration more effectively. It shortened the latent phase by 3.0 hours (95% credible intervals [CrI], 2.2 to 3.9) compared with dexamethasone (1.8 hours; 95% CrI, 1.2 to 2.4) and the active phase by 1.99 hours (95% CrI, 1.03 to 2.99) compared with 1.09 hours (95% CrI, 0.54 to 1.71), with a posterior probability of superiority exceeding 99.9%. All neonates had Apgar scores ≥8.
conclusionIntravaginal MgSO4 produced cervical effacement and dilation comparable to IV dexamethasone but achieved a significantly greater reduction in labor duration. Given similar neonatal safety outcomes, these findings suggest that intravaginal MgSO4 may be a preferable first-line agent for labor acceleration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.